Second, FLZ treatment significantly downregulated human epidermal growth factor receptor (HER)-2-related signaling in HER2-positive breast cancer and induced apoptosis in trastuzumab-resistant cell lines as well as in sensitive cell lines [58], which indicates its potential for use as a substitute or supplement for trastuzumab. Here, ERBB2 is linked to breast cancer.